Get the Stockscreener App
8.47
0.24%
0.02
Pre-market:
8.58
0.11
+1.30%
Immix Biopharma Inc stock is traded at $8.47, with a volume of 970.59K.
It is up +0.24% in the last 24 hours and down -14.79% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$8.45
Open:
$8.58
24h Volume:
970.59K
Relative Volume:
0.95
Market Cap:
$602.98M
Revenue:
-
Net Income/Loss:
$-34.98M
P/E Ratio:
-9.2075
EPS:
-0.9199
Net Cash Flow:
$-32.77M
1W Performance:
+7.62%
1M Performance:
-14.79%
6M Performance:
+36.50%
1Y Performance:
+260.43%
1-Day Range:
$8.25
$8.79
1-Week Range:
$7.80
$8.79
52-Week Range:
$1.94
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.47 | 602.98M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
IMMX Q1 2026 Earnings: Biotech Reports Narrower-than-Expected Loss, Shares GainEPS Estimate Trend - newsline.com
Immix Biopharma Surges 5.3% as Biotech Sentiment Lifts IMMXProfit Surge Picks - newsline.com
Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high? - MSN
What's going on with Immix Biopharma stock Thursday? - MSN
Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX) - Stock Titan
IMMX News | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
IMMX Technical Analysis | Trend, Signals & Chart Patterns | IMMIX BIOPHARMA INC (NASDAQ:IMMX) - ChartMill
Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026) - Minichart
Immix Biopharma Shareholders Back Board and Auditor at AGM - TipRanks
Immix Biopharma (NASDAQ: IMMX) posts 2026 annual shareholder voting outcomes - Stock Titan
Immix Biopharma (IMMX) awards RSUs and stock options to director Helen Adams - Stock Titan
Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option - Stock Titan
Immix Biopharma (NASDAQ: IMMX) grants RSUs and stock options to director - Stock Titan
Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78 - Stock Titan
Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options - Stock Titan
Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike - Stock Titan
Immix Biopharma (IMMX) director awarded RSUs and stock options in new grants - Stock Titan
Immix Biopharma (IMMX) board member receives new RSU and stock option awards - Stock Titan
Immix Biopharma (IMMX) director Jane Buchan awarded RSUs and 12,500 stock options - Stock Titan
Immix Biopharma (IMMX) Edges Higher as Biotech Sentiment ShiftsLiquidity Order Flow - newsline.com
Immix Biopharma Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock UptickQuarterly Profit Report - newsline.com
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High? - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX) - The Globe and Mail
Mizuho Securities Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Immix Biopharma closes $140.65 million offering - The Pharma Letter
Immix Biopharma stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
IMMX Q1 2026 Earnings: Narrowed Loss as Biotech Advances Oncology PipelineEarnings Outlook Update - Newser
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Immix Biopharma closes $140.65 million stock offering By Investing.com - Investing.com Australia
Immix Biopharma Announces Closing of $150 Mil - Moomoo
Immix Biopharma closes $140.65 million stock offering - Investing.com UK
IMMX Maintained by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus
Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common Stock - Quiver Quantitative
Biotech Immix Biopharma pulls in $140.65M from new stock sale - Stock Titan
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Immix Biopharma Price Target Raised to $20.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright - TipRanks
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - Sahm
Immix Biopharma Announces $150 Million Stock Offering to Fund NXC-201 AL Amyloidosis Therapy Development - Minichart
Immix Biopharma Raises $150 Million to Advance NXC-201 - TipRanks
Immix Biopharma (NASDAQ: IMMX) prices $150M common stock sale - Stock Titan
Immix Biopharma (IMMX) to raise ~$140.7M net via 16.78M-share sale - Stock Titan
What's Going On With Immix Biopharma Stock Thursday? - Benzinga
Immix Biopharma Prices $150 Million Stock Offering - Moomoo
Immix Biopharma prices $150 million stock offering at $8.94 By Investing.com - Investing.com South Africa
Immix Biopharma reports 95% complete response rate in trial By Investing.com - Investing.com South Africa
Sector Update: Healthcare - Moomoo
Immix Biopharma prices $150 million stock offering at $8.94 - Investing.com
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):